A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

CRS - Cytokine Release Syndrome · Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Contact: Study coordinator (Gang An) · angang@ihcams.ac.cn · 86-022-23909171

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Cytokine Release Syndrome · Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Columbus, United States

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Lymphoma · Myeloma · Cytokine Release Syndrome

Abroad (travel likely)Recruiting

Salt Lake City, United States

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Non-Hodgkin Lymphoma · Cytokine Release Syndrome

Abroad (travel likely)RecruitingPHASE1

Cleveland, United States

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Ampang, Malaysia